In This Article:
-
Total Revenue (Q4 2024): $5.2 million, up 8% from $4.8 million.
-
Recurring Revenue (Q4 2024): Essentially 100% of total revenue.
-
Operating Expenses (Q4 2024): $3.9 million, up 6% from $3.6 million.
-
GAAP Net Income (Q4 2024): $1.6 million, up 15% from $1.4 million.
-
GAAP Net Income to Common Shareholders (Q4 2024): $1.5 million, up 18% from $1.2 million.
-
Earnings Per Share (Q4 2024): $0.08, up from $0.07 last year.
-
Preferred Stock Redemption (Q4 2024): 81,000 shares at $10.70 per share, totaling just under $870,000.
-
Total Revenue (Fiscal Year 2024): Up 7%, with recurring revenue at 99% of total revenue.
-
Operating Expenses (Fiscal Year 2024): Increased 10%.
-
GAAP Net Income (Fiscal Year 2024): $5.9 million, up 7% from $5.6 million.
-
GAAP Net Income to Common Shareholders (Fiscal Year 2024): $5.4 million, up 8% from $5 million.
-
Earnings Per Share (Fiscal Year 2024): $0.30 basic and $0.29 diluted, up from $0.27 last year.
-
Common Shares Repurchased (Fiscal Year 2024): 177,000 shares for $1.5 million.
-
Preferred Shares Redeemed (Fiscal Year 2024): 220,000 shares at $10.70 per share, totaling $2.4 million.
-
Cash Dividends Paid (Fiscal Year 2024): $1.7 million to common shareholders.
-
Total Cash (June 30, 2024): $25.2 million, up from $24 million at the end of fiscal year 2023.
-
Cash Generated from Operations (Fiscal Year 2024): Nearly $7 million.
-
Common Stock Buyback Authorization Remaining: $8 million out of $21 million total.
-
Quarterly Common Stock Dividend Increase: 10% starting with shareholders of record on December 31, 2024.
Release Date: September 30, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Increased recurring revenue and delivered solid margins.
-
Grew net income and EPS faster than anticipated.
-
Added more cash to the balance sheet, reaching the highest in the company's history.
-
Returned over $5.6 million in capital to shareholders through dividends, buybacks, and redemption of preferred shares.
-
Invested heavily in sales, marketing, cybersecurity, and development platforms to accelerate traceability solutions.
Negative Points
-
Operating expenses increased by 10%, reflecting investments in various areas.
-
Eliminated $1.4 million of high-touch, low-opportunity revenue, which impacted comparative growth.
-
Complex multi-step process for enrolling suppliers due to FDA mandates, making forecasting difficult.
-
High dependency on the FDA's timeline for traceability requirements, which could change.
-
Significant resources required for onboarding suppliers, many of whom lack necessary IT infrastructure.